Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 13vPnC with TIV in Adults 50-59 Years
NCT00521586Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2007
- Primary completion
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Prevnar 13 in pneumococcal disease, sponsored by Pfizer. Started Sep 2007; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT00521586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521586.